Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia.
US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
